<DOC>
	<DOCNO>NCT00423592</DOCNO>
	<brief_summary>This Phase 2 study determine incidence increase serum aminotransferase concentration ( alanine aminotransferase [ ALT ] and/or aspartate aminotransferase [ AST ] ) , well overall safety tolerability ambrisentan , participant pulmonary arterial hypertension ( PAH ) , idiopathic PAH ( IPAH ) , familial PAH ( FPAH ) previously discontinue ERA therapy ( bosentan sitaxsentan ) due increase serum ALT AST concentration .</brief_summary>
	<brief_title>Phase 2 Study Ambrisentan Liver Function Test Rescue Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>Summary Males Females 12 75 year age Current diagnosis IPAH , FPAH , PAH associate collagen vascular disease , congenital systemictopulmonary shunt , anorexigen use , HIV infection Must previously discontinue bosentan sitaxsentan therapy due serum aminotransferase ( ALT and/or AST ) concentration &gt; 3 x ULN Must normal ( &lt; 1 x ULN ) serum ALT AST concentration screen Sixminute Walk distance least 150 meter screen If receive sildenafil clinically approve prostanoid PAH , must stable therapy least 4 week prior screen Subjects diagnosis HIV must stable disease status screen period</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>